Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 in Type 1 Diabetes
NCT07142161Phase 1Active, not recruiting
- Sponsor
- Bioheng Therapeutics
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-02 in type 1 diabetes mellitus (T1D), sponsored by Bioheng Therapeutics. Primary endpoints: Dose-Limiting Toxicity at 1 year and Incidence of Adverse Events at 1 year. Started Jul 2025; status: active, not recruiting.
02
Drugs
RD13-02
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07142161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142161.